Revolution in Cancer Treatment: Breakthrough Drug Offers New Hope for Leukemia Patients
Olverembatinib is a new third-generation BCR-ABL inhibitor approved in China, offering hope for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. This groundbreaking drug is included in China’s National Reimbursement Drug List, highlighting its potential to transform
